Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...
—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...
Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer ...
Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...
In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing. He will review the NSCLC ...
Differential patterns of cell surface marker expression in clinically relevant subgroups of non-small cell lung cancer. Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to ...
The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared ...
Sarcopenia is emerging as a potential predictor of adverse outcomes for some solid tumors, but could this physical biomarker effectively stratify risk in patients with non-small cell lung cancer ...
(A) NKAPL expression levels in human lung cancer cell lines (A549, H1299, H358, NCI-H446, NCI-H460, NCI-H2122, NCI-H1651, CHAGO-K-1, and SW1271) and normal lung tissues (#1, #2) were detected via ...
The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback